TMCnet - World's Largest Communications and Technology Community



Anacor Pharmaceuticals to Present at the UBS Global Health Care Conference
[May 13, 2014]

Anacor Pharmaceuticals to Present at the UBS Global Health Care Conference

PALO ALTO, Calif. --(Business Wire)--

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company's President and Chief Executive Officer, will provide a company overview at the UBS Global Health Care Conference on Monday, May 19, 2014 at 4:00 p.m. ET in New York, New York. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at A replay will also be available for three months following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and ommercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor's two lead product candidates are topically administered dermatologic compounds - Kerydin, a topical antifungal in development for the potential treatment of mild-to-moderate onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. In addition to its two lead product candidates, Anacor has discovered three other wholly-owned clinical product candidates - AN2718 and AN2898, which are backup compounds to Kerydin and AN2728, respectively, and AN3365, an antibiotic in development for the treatment of infections caused by Gram-negative bacteria. Anacor has also discovered three other compounds that have been out-licensed for further development - one is licensed to Eli Lilly and Company for the treatment of an animal health indication, the second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness) and the third compound is licensed to GlaxoSmithKline, LLC for tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in earlier stages of research and pre-clinical development. For more information, visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy